Enliven Therapeutics ELVN Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $98.9M-20.3% | $124.12M+23.9% | $100.14M+32.6% | $75.54M+56.4% | ||
| $363.73M+92.1% | $189.32M+23.7% | $153.01M— | $0-100% | ||
| $474.88M+49.3% | $318.13M+19.5% | $266.15M+242% | $77.75M-16.1% | ||
| $34K-92.6% | $458K-38.3% | $742K-16.6% | $890K+256% | ||
| $476.17M+46.2% | $325.76M+19.8% | $271.87M+226% | $83.3M-11.1% | ||
| $7.5M+21.6% | $6.17M-42.5% | $10.73M+48.5% | $7.22M-31.0% | ||
| $16.57M+4.1% | $15.92M-38.5% | $25.89M+167% | $9.72M+34.7% | ||
| $16.57M+4.1% | $15.92M-38.7% | $25.96M+150% | $10.37M+36.2% | ||
| $59K+20.4% | $49K+19.5% | $41K+4,000% | $1K-96.3% | ||
| -$347.17M-42.6% | -$243.47M-57.6% | -$154.45M-86.4% | -$82.86M+43.8% | ||
| $459.6M+48.3% | $309.85M+26.0% | $245.91M+420% | -$76.83M-79.1% | ||
| $476.17M+46.2% | $325.76M+19.8% | $271.87M+226% | $83.3M-11.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Enliven Therapeutics's total assets?
- Enliven Therapeutics (ELVN) holds $464.9M in total assets, up 53.6% year over year.
- How much debt does Enliven Therapeutics have?
- Enliven Therapeutics carries $302.0K in total debt against $453.4M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Enliven Therapeutics have?
- Enliven Therapeutics holds $132.2M in cash and equivalents.
- Can Enliven Therapeutics cover its short-term obligations?
- Its current ratio is 40.32 — current assets exceed current liabilities.
- Where does Enliven Therapeutics's balance sheet data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.